Study of Tirzepatide for Recovery and Alcohol Use Management

NCT06727331 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication tirzepatide can help reduce cravings for alcohol in adults with alcohol use disorder.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 20 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-09 · est. completion 2026-07

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06727331 ↗

Description as written by the study sponsor.

This is a pilot, 4-week, double-blind, placebo-controlled, randomized trial of individuals with alcohol use disorder (AUD) to receive weekly injections of either tirzepatide (n=10) or matching placebo (n=10). The primary aim is to determine the effects of tirzepatide on cue-reactivity among individuals with AUD. The secondary aim is to assess the safety and preliminary efficacy of tirzepatide for AUD.

Treatments tested

Tirzepatide also known as Mounjaro Drug

This intervention will consist of the FDA-approved dosing schedule. Participants will receive 2.5mg weekly injections for 4 weeks. IDS will extract tirzepatide and draw the doses into syringes.
Saline Placebo Other

Placebo syringes of saline and matching volume will be produced by IDS.

Main thing measured	Cue-induced Cravings for Alcohol
Sponsor	Brigham and Women's Hospital
Conditions studied	Alcohol Use Disorder (AUD)
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06727331 ↗